Donor-Derived CAR T Cells Targeting BCMA for Multiple Myeloma That Returned or Resisted Treatment
Tests donor-derived BCMA CAR T cells in adults with relapsed or refractory multiple myeloma.
Plain-language title generated from the registry record
Registry title: Universal CAR-T Cell Therapy for MM
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Shanghi Tongji Hospital (Tongji Hospital of Tongji University)Shanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bioray Laboratories
- Trial code
- NCT07248176
- Record updated
- 1 December 2025
- Original description
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.Read full original descriptionShow less
A Clinical Study on the Safety and Efficacy of Allogeneic CAR T Cells Targeting BCMA in the Treatment of Adult r/r Multiple Myeloma
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Inclusion: Expected survival of at least 3 months; Subjects should have measurable disease that meets the IMWG 2016 criteria; Previously received at least two lines of prior anti-myeloma therapy ；; Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；; BCMA positive；; ECOG score 0-1；; No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function.
Exclusion: Previously received allogeneic stem cell transplantation; Previous use of CAR-T cells or other genetically modified T cell therapies; Previously received targeted BCMA therapy; History of other malignant tumors; Active autoimmune diseases requiring immunotherapy; Severe cardiovascular disease; Active infection; Clinically significant central nervous system (CNS) diseases or pathological changes; Pregnant or breastfeeding women; Positive virology test.